D. E. Shaw & Co., Inc. Viking Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding VKTX
# of Institutions
443Shares Held
63.4MCall Options Held
6.23MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$656 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$391 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$333 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$146 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$121 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.98B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...